Abstract
Background While the amplification of oncogenes (such as EGFR, c-ERBB2, c-MYC, and c-MET) are increasingly driving decision-making for precise cancer treatments, a feasible method to detect somatic copy number deletion (SCND) of tumor suppressor genes is still absent to date.
Methods The genomic coordinates of gene deletion fragments were analyzed using the Catalogue Of Somatic Mutation In Cancer (COSMIC) datasets. Interstitial base-resolution deletion/fusion coordinates for CDKN2A were extracted from published articles and our whole genome sequencing (WGS) datasets. The copy number of the CDKN2A gene was measured with a multiplex quantitative PCR assay P16-Light and confirmed with whole genome sequencing (WGS).
Results Estimated common deletion regions (CDRs) were observed in many tumor suppressor genes, such as ATM, CDKN2A, FAT1, miR31HG, PTEN, and RB1, in the SNP array-based COSMIC datasets. A 5.1-kb base-resolution CDR could be identified in >90% of cancer samples with CDKN2A deletion by sequencing. The CDKN2A CDR covers exon-2, which is essential for P16INK4A and P14ARF synthesis. Using the true CDKN2A CDR as a PCR target, a multiplex quantitative PCR assay P16-Light was programmed to detect CDKN2A gene copy number with a lower detection limit of 20%. P16-Light was further confirmed with WGS as the gold standard among cancer tissue samples from 139 patients.
Conclusion CDRs are common in many tumor suppressor genes. The 5.1-kb CDKN2A CDR was found in >90% of cancers containing CDKN2A deletion. The CDKN2A CDR was used as a potential target for developing the P16-Light assay to detect CDKN2A SCND and amplification for routine clinical practices.
Competing Interest Statement
DD, YT, JZ, and ZL are the creators for the pending patent "A quantitative method for detection of human CDKN2A gene copy number using a primer set and their applications" (PCT/CN2019/087172; WO2020228009).
Funding Statement
This work was supported by the Beijing Natural Science Foundation (grant number 7181002 to DD) and Beijing Capital's Funds for Health Improvement and Research (grant number 2018-1-1021 to DD).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institution Review Board of Peking University Cancer Hospital & Institute approved this study and was carried out in accordance with the principles outlined in the Declaration of Helsinki. Informed consent was obtained from each patient prior to their inclusion in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
A number of typo were corrected.
Data Availability
Supplementary Figures 1-3 and Data files 1-14 are attached.
